Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05005351 · ClinicalTrials.gov registry record · Phase 2
"SMART-FM": Smart-Phone Based Digital Therapeutic for Management of Fibromyalgia
A Phase 2 study, sponsored by Swing Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 67
- Enrollment target
NCT05005351 is a Phase 2 study that has completed, run by Swing Therapeutics. The registered enrollment target is 67 participants.
The verdict
NCT05005351, a Phase 2 study, has completed, sponsored by Swing Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 67 participants
- Enrollment target
Study Summary
This is a non-significant risk, multi-center, randomized, active-controlled study to compare the effectiveness of two digital therapies in the management of fibromyalgia over 12 weeks. The primary endpoint is mean change from baseline to Week 12 in the weekly revised Fibromyalgia Impact Questionnaire (FIQ-R) total score.
Interventions
- DEVICE Digital ACT
- DEVICE Digital Symptom Tracker
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2020-10-28 |
| Est. Completion | 2021-07-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05005351
The ClinicalTrials.gov registry entry for NCT05005351 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Swing Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Digital ACT is the first listed.
NCT05005351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05005351 about?
NCT05005351 is a clinical study titled ""SMART-FM": Smart-Phone Based Digital Therapeutic for Management of Fibromyalgia". This is a non-significant risk, multi-center, randomized, active-controlled study to compare the effectiveness of two digital therapies in the management of fibromyalgia over 12 weeks. The primary endpoint is mean change from baseline to Week 12 in the weekly revised Fibromyalgia Impact Questionnair...
What is the current status of trial NCT05005351?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 67 participants. The study started on 2020-10-28. Estimated completion is 2021-07-09.
What interventions are being tested in trial NCT05005351?
The interventions under investigation include: Digital ACT (DEVICE), Digital Symptom Tracker (DEVICE).
Who is sponsoring clinical trial NCT05005351?
This trial is sponsored by Swing Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.